Researchers at Wake Forest Baptist Medical Center have announced results of a study in which 60 patients with amnesic mild cognitive impairment or mild to moderate Alzheimer’s dementia received one of two doses of an insulin detemir nasal spray or placebo for 21 days.
According to the authors, patients receiving the higher dose (40 IU), demonstrated significant improvements in short term memory, especially those patients with the APOE-e4 gene. The study will be published in the February 2015 issue of the Journal of Alzheimer’s Disease.
Lead author Suzanne Craft, Professor of Gerontology and Geriatric Medicine, said, “The study provides preliminary evidence that insulin detemir can provide effective treatment for people diagnosed with mild cognitive impairment and Alzheimer’s-related dementia similar to our previous work with regular insulin. We are also especially encouraged that we were able to improve memory for adults with MCI who have the APOE-e4 gene, as these patients are notoriously resistant to other therapies and interventions.”
Read the Wake Forest Baptist Medical Center press release.
Read the abstract.
